Member Info for ciaskin

Title: “Cancer vaccines are the new kid on the block: making cancer immunotherapy work better”

Https://x.com/livHeadandNeck/status/1856336299059216626?t=YCjK-42dvw5iXZ4TfFdoVQ&s=19

Nice find Berm. I also think some of the 41 comments to his LI post about leaving CatalYm are also telling. I particularly like:

"CatalYm would not have been in the same place without your leadership and dedication. Wherever you will continue being the CEO, they are indeed extremely lucky getting you!!"

Https://www.linkedin.com/in/phil-l-huillier-54788b

This has reminded me of my prediction on 17th September, pasted below:

My money is on an announcement exactly four weeks from today, on October 15th, the day before we speak at the Festival of Biologics in Basel. Subject: : Clinical update on the DC targeting melanoma vaccine, SCIB1 and the Modi-1 vaccine targeting citrullination.

And it's a Tuesday!

If you're planning on paying for your grandchildren's education, Cleaner, remember to add another 20% for VAT!

We strongly believe we will continue to demonstrate the therapeutic potential of SCIB1/iSCIB1+ in advanced melanoma and deliver one of the world’s first off-the-shelf cancer vaccines while creating and delivering significant long-term value for our shareholders.

Jean-Michel Cosséry, Chairman

My money is on an announcement exactly four weeks from today, on October 15th, the day before we speak at the Festival of Biologics in Basel. Subject: : Clinical update on the DC targeting melanoma vaccine, SCIB1 and the Modi-1 vaccine targeting citrullination.

And it's a Tuesday!

Scancell mention at 22.48

Stephen Nolan show: feature about Cancer Vaccines on now. 22.35

Interviewee from Imperial College (who are doing pre-clinical work on their own vaccine) but good advocacy for cancer vaccines being the way to go...

Interview on cancer vaccines on Radio 4 now. Catch up on BBC Sounds from 7.14 am

And don't forget that around the time of the Roche speculation/Moditope discovery, the SP rose as high as 60p. I know because I bought some!

There she goes...Straight up to 19p on the ask on HL

I think that Ruck's point may be that Sardesai isn't "someone within Scancell" who is agreeing with Inanaco. He is at Geneos Therapeutics who are developing individualized DNA-based vaccines for each patient. However, taken in the context of the vaccine sector (rather than just what Geneos are doing) it is another clear sign of encouragement.

Https://www.immuno-oncologysummit.com/cancer-vaccines

11:55 am

modi-2, a vaccine targeting ****citrullinated self-epitopes, stimulates potent cd4-mediated anti-tumor responses as a therapy for solid cancers

abdullah al-omari, phd, scientist, t cell vaccine, scancell ltd.

stresses within the tumor microenvironment mediate post-translational modifications of self-proteins. ****citrullination is the conversion of lysine residues to ****citrulline which can generate neoepitopes and bypass self-tolerance. modi2, a ****citrullinated peptide-snapvax vaccine, stimulates strong th1 responses and anti-tumor immunity in three different murine tumor models. we propose the modi-2 vaccine formulation has potential for translation into clinic in several cancer indications.

Great find Berm! Thanks for posting.

Or to put it another way, two out of three DON'T respond to BioNTech's MRNA vaccine...

So is the subject line wrong too? i.e Scancell appoints Dr Nermeen Varawalla as new CMO? https://www.linkedin.com/in/nermeen-varawalla